393165-02-1

Basic information

• Product Name: (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester
• Synonyms: (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester
• CAS NO: 393165-02-1
• Molecular Weight: 244.699
• Mol File: 393165-02-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester(393165-02-1)
• EPA Substance Registry System: (3-chloro-4-methylsulfanyl-phenyl)-oxo-acetic acid methyl ester(393165-02-1)

Safety Data

• Hazardous Substances Data: 393165-02-1(Hazardous Substances Data)

Upstream product

• 5781-53-3 monomethyl oxalyl chloride 
• 17733-22-1 2-chlorothioanisole 
• 71556-63-3 o-methoxybenzenesulfenyl chloride 

Downstream Products

• 1033780-24-3 C₂₅H₂₅ClN₄O₆S 
• 1033780-25-4 C₂₅H₂₄Cl₂N₄O₅S 
• 1033780-02-7 (E)-4-{3-[2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-acetylamino]-pyrazol-1-ylmethyl}-benzamide 
• 1033780-15-2 (E)-N-[1-(3-acetylamino-benzyl)-1H-pyrazol-3-yl]-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-acetamide 
• 1033780-00-5 (E)-4-{3-[2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-acetylamino]-pyrazol-1-ylmethyl}-benzoic acid methyl ester 
• 1033780-08-3 (E)-N-(6-chloro-benzothiazol-2-yl)-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-acetamide 
• 1033780-14-1 (E)-N-(5-benzyl-[1,3,4]thiadiazol-2-yl)-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-acetamide 
• 1033780-07-2 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(6-methoxy-benzothiazol-2-yl)-acetamide 
• 1033779-97-3 (E)-2-[2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclohexyloxyimino-acetylamino]-thiazole-5-carboxylic acid amide 
• 1033780-12-9 (E)-N-(3-benzyl-[1,2,4]thiadiazol-5-yl)-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-acetamide 
• 1033780-01-6 (E)-2-[2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-acetylamino]-thiazole-5-carboxylic acid amide 
• 1033779-96-2 (E)-N-benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclohexyloxyimino-acetamide 
• 1033780-16-3 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(1-pyridin-3-ylmethyl-1H-pyrazol-3-yl)-acetamide 
• 1033779-99-5 (E)-N-benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-acetamide 

Relevant articles and documents

Discovery of piragliatin-first glucokinase activator studied in type 2 diabetic patients

Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies.

5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS

The present invention provides a compound according to formula (I) where the substituent designations are provided in the specification. Pharmaceutical compositions comprising a compound according to formula (I) are also provided, said compounds being glucokinase activators which are useful in the treatment of type II diabetes.

HETEROAROMATIC GLUCOKINASE ACTIVATORS

-